ProOnc TumorSource Dx identifies the tissue-of-origin of a metastatic tumor.
The test identifies 25 different tumor types, including colon, liver, brain,
breast, kidney, lung, ovary, pancreas, prostate and testis, and measures the
expression level of 48 microRNA biomarkers. ProOnc TumorSource Dx uses a
proprietary classifier to assign a primary site to the cancer sample based on
the microRNA expression in the tumor and may become a critical tool in the
detection of cancer of unknown primary (CUP).
ProOnc Squamous Dx classifies non-small cell lung carcinoma tumors into two
histological groups: cancers of squamous histology and non-squamous cancers.
The test measures the expression level of a squamous microRNA biomarker to
differentiate patients that have squamous cell carcinoma of the lung from
patients that have non-squamous non-small cell lung cancer.
ProOnc Mesothelioma Dx is a cutting-edge molecular diagnostic test that uses
microRNA to differentiate malignant pleural mesothelioma from peripheral
adenocarcinoma of the lung and metastatic carcinomas involving the lung and
pleura.
"MicroRNAs are small, non-coding sequences of RNA that are critically
important in many biological and pathological processes," said Harvey Pass,
M.D., Professor of Cardiothoracic Surgery and Director of the Division of
Thoracic Surgery and Thoracic Oncology at New York University Langone Medical
Center and its NYU Cancer Institute. "The sensitivity and specificity of
microRNA-based diagnostics should enable clinicians to differentiate
particular cancer tissues with increased confidence, which may ultimately
guide medical oncologists to deliver the safest and most efficacious therapy
for their patients."
For more information about ProOnc Dx tests, please call (877) 378-4919 or
visit www.prometheusoncology.com.
Prometheus acquired exclusive U.S. rights to ProOnc TumorSource Dx, ProOnc
Squamous Dx and ProOnc Mesothelioma Dx from Rosetta Genomics (Nasdaq: ROSG) in
April 2009. The tests are offered as miRview mets, miRview squamous and
miRview meso outside of the U.S. In addition, Prometheus and Rosetta are
collaborating to develop two new microRNA-based gastroenterology tests.
About Prometheus
Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostic
company committed to developing and commercializing novel pharmaceutical and
diagnostic products to help physicians individualize patient care. Prometheus
is a leader in applying the principles of personalized medicine to the
diagnosis and treatment of gastrointestinal diseases and is applying these
principles to oncology. Its strategy includes the marketing and delivery of
pharmaceutical products complemented by proprietary diagnostic testing
services. By integrating pharmaceutical products and diagnostic testing
services, Prometheus believes it can address the full continuum of care,
thereby providing physicians with a comprehensive solution to treat chronic
diseases. Prometheus' corporate offices are located in San Diego.
ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx are
trademarks of Prometheus Laboratories Inc. miRview mets, miRview squamous and
miRview meso are trademarks of Rosetta Genomics Ltd.
SOURCE Prometheus Laboratories Inc.
Pete De Spain, Director, Investor Relations & Corporate Communications of
Prometheus Laboratories Inc., +1-858-587-4117, pdespain@prometheuslabs.com; or
John F. Kouten, Chief Executive Officer of JFK Communications, Inc.,
+1-609-514-5117,
